Treatment
AGS, death
The maximum total daily dose of baricitinib ranged from 8 to 12 mg. The median (range) duration of exposure to baricitinib was 52.1 (8.4–53.1) weeks. Among patients with NNS/CANDLE, the minimum and maximum duration of exposure was 13.3 weeks and 52.4 weeks, respectively. In patients with SAVI, the minimum and maximum duration of exposure was 8.4 weeks and 53.0 weeks, respectively; 1 patient discontinued early due to death and 1 patient was enrolled in the study after primary data cutoff and did not complete 52 weeks as of April 2022. In the patient with AGS, the duration of exposure was 53.1 weeks. Patients were deemed compliant if they missed < 20% of the expected number of doses; all patients were compliant in the study.